These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7868848)

  • 1. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer patients.
    Ahlin A; Adem A; Junthé T; Ohman G; Nybäck H
    Int Clin Psychopharmacol; 1992; 7(1):29-36. PubMed ID: 1624754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study.
    Gauthier S; Bouchard R; Lamontagne A; Bailey P; Bergman H; Ratner J; Tesfaye Y; Saint-Martin M; Bacher Y; Carrier L
    N Engl J Med; 1990 May; 322(18):1272-6. PubMed ID: 2183056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.
    Lou G; Montgomery PR; Sitar DS
    J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nose-to-brain delivery of tacrine.
    Jogani VV; Shah PJ; Mishra P; Mishra AK; Misra AR
    J Pharm Pharmacol; 2007 Sep; 59(9):1199-205. PubMed ID: 17883890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine.
    Itil TM; Eralp E; Ahmed I; Kunitz A; Itil KZ
    Psychopharmacol Bull; 1998; 34(3):391-7. PubMed ID: 9803773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.
    Summers WK; Majovski LV; Marsh GM; Tachiki K; Kling A
    N Engl J Med; 1986 Nov; 315(20):1241-5. PubMed ID: 2430180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting patients with Alzheimer's disease suitable for drug treatment: comparison of three methods of assessment.
    Wilcock GK; Ashworth DL; Langfield JA; Smith PM
    Br J Gen Pract; 1994 Jan; 44(378):30-3. PubMed ID: 8312036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrine therapy for the dementia of Alzheimer's disease.
    Manning FC
    Am Fam Physician; 1994 Sep; 50(4):819-26. PubMed ID: 8079912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experiences and biochemical findings with tacrine (THA).
    Nybäck H; Hassan M; Junthé T; Ahlin A
    Acta Neurol Scand Suppl; 1993; 149():36-8. PubMed ID: 7510447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy.
    Boller F; Orgogozo JM
    Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential effect of tacrine on expenditures for Alzheimer's disease.
    Lubeck DP; Mazonson PD; Bowe T
    Med Interface; 1994 Oct; 7(10):130-8. PubMed ID: 10172130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS].
    Fredj G; Dietlin F; Barbier G; Jasmin C; Bonhomme L; Esctein S; Misset JL; Meyer P; Kalifa D; Beugre T
    Therapie; 1992; 47(3):245-7. PubMed ID: 1295125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.
    Kumar V; Becker RE
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):478-85. PubMed ID: 2684868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
    Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
    J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.